Angela Lamb, MD: Breaking the Itch-Scratch Cycle in Prurigo Nodularis

April 15, 2026

Angela Lamb, MD, an associate professor of dermatology at the Icahn School of Medicine at Mount Sinai in New York, discusses recent advancements in understanding and treating prurigo nodularis and chronic itch disorders. She highlights the role of interleukin (IL)-31 in driving the itch-scratch cycle. She explains that nemolizumab (Nemluvio) targets the IL-31 receptor, which is expressed on dorsal root ganglion cells, mast cells, basophils, and keratinocytes, helping to disrupt key itch signaling pathways.

Topics Covered:

Understanding pruritus and its impact on patients with prurigo nodularis
Mechanism of action and immunological insights
Efficacy and safety of nemolizumab

MORE EXPERT PERSPECTIVES IN PRURIGO NODULARIS:

David Cotter, MD, PhD: Patient Presentation and Clinical Trial Data for Prurigo Nodularis

Dr. Cotter, a board-certified dermatologist at Las Vegas Dermatology, presents a real-world case of Prurigo Nodularis, highlighting both the severity of disease presentation and the

Jenny Murase, MD: Assessing Symptoms and Presentation of Patients with Prurigo Nodularis

Dr. Murase reviews the clinical presentation of Prurigo Nodularis, a chronic inflammatory skin condition characterized by intensely pruritic nodules and significant disease burden. She outlines

James Del Rosso, DO, and David G. Cotter, MD, PhD: Targeting the IL-31 Neuroimmune Pathway for Treating Prurigo Nodularis

Drs. Del Rosso and Cotter discuss how advances in the molecular understanding of Prurigo Nodularis have led to the development of targeted therapies that address

Diego Ruiz Dasilva, MD, FAAD: Providing Treatment for Challenging Cases of Chronic Pruritus

Dr. Dasilva presents findings from a real-world case series evaluating treatment options for patients with treatment-resistant chronic pruritus, highlighting the marked efficacy of Nemolizumab. His

JCAD Archives